



DEEP Study phase 2 Questions & Answers

1. NOW YOU HAVE COMPLETED THE PHASE 2 STUDY, DOES THIS MEAN THAT THE PRODUCT WILL BE ON THE MARKET SOON?

This initial study in pregnant women (23-34 weeks) met one of its primary objectives. However, further analysis of the data needs to be completed before we understand what direction this programme will take. The product is at an early stage of its development and if it is going to be developed further it will need to go through larger studies. These studies will take several years.

2. IF THIS PRODUCT IS NOT AVAILABLE, WHAT OTHER TREATMENTS CAN BE USED?

For many years, doctors have managed the symptoms of pre-eclampsia with existing drugs, such as anti-hypertensives to lower blood pressure and anti-convulsants, but there is currently no treatment which tackles the underlying cause of the disease. Protherics advises pregnant women to consult with their doctor if feeling unwell.

3. WHERE CAN I GET FURTHER INFORMATION ON THE STUDY?

The full study design is available at
<http://www.clinicaltrials.gov/ct/show/NCT00158743?order=7>

4. WHERE CAN I GET FURTHER INFORMATION ON THE DISEASE AREA?

You can obtain further information on pre-eclampsia from your physician or one of the patient support groups, such as the 'Pre-eclampsia Foundation' in the US and 'Action on Pre-eclampsia' in the UK.

5. HOW CAN I ENTER INTO A CLINICAL STUDY?

We are still evaluating the phase 2 study results and, as yet, no decisions have been made about when and where future clinical studies will be undertaken. Updated information will be available on our web site at a later date.

6. CAN MY DOCTOR GIVE ME DIGIBIND[®] IF I HAVE PRE-ECLAMPSIA?

Digibind[®] is only licensed for treating digoxin toxicity and therefore use of this drug in pre-eclampsia is very limited. Please consult with your treating physician.